IMARC Group in its latest study entitled “Global Healthcare Cold Chain Logistics Market Report & Forecast (2011-2016)” finds that the increasing growth of the biosimilar market is expected to expand the demand of cold chain logistic services in the coming years. Findings from the report suggest that biosimilars are expected to cost 20% – 60% less than their branded counterparts and, as a result, will become more affordable for both patients and healthcare providers. The study expects the entry of biosimilars to expand the overall patient pool of these drugs and thereby increasing their overall shipment volumes. Findings also suggested that a number of key biosimilar manufactures are expected to be based in Asian Countries. Since the manufacturing facilities of these companies will be based in Asia and their end user markets in the US and Europe, the study expect a significant increase of biopharmaceutical exports between these regions.

IMARC’s report entitled “Global Healthcare Cold Chain Logistics Market Report & Forecast (2011-2016)” provides an analytical and statistical insight into the logistic opportunities in the global healthcare market. The study that has been undertaken using both desk based as well as qualitative primary market research has analyzed three aspects of the global healthcare cold chain logistics market.
What we have achieved in this report:

Comprehensive Market Analysis of Temperature Sensitive Healthcare Products:
Classes Covered: Biopharmaceuticals, Vaccines & Clinical Trial Materials
Focus of the Analysis in Each Class:
• Drivers and challenges
• Historical sales trends
• Logistic requirements
• Impact of temperature excursions
• Opportunities in cold chain services
• Market outlook (2011-2016)

Understanding the Operations of a Healthcare Cold Chain Distribution Process
Focus of the Analysis:
• Understanding the various methods of cold chain distribution and their advantages/disadvantages
• Understanding the cold chain requirements for various temperature sensitive healthcare products and the impact of temperature excursions
• Understanding the various costs involved in cold chain transportation and comparing it with non-cold chain transportation
• Understanding the key steps required in the setting and organization of an efficient cold chain distribution process

Comprehensive Market Analysis of the Healthcare Cold Chain Logistic Services Market
Focus of the analysis:
• Quantifying the global healthcare cold chain logistic services market
• Quantifying the market size by product
• Quantifying the market size by service
• Quantifying the market size by region

Information Sources:
Information has been sourced from both primary and secondary sources:
• Primary sources include industry surveys and face to face/telephone interviews with industry experts.
• Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.

To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
To know more please visit: http://www.imarcgroup.com/

Although they are not harmful to humans, ACP can prove devastating for citrus trees — such as oranges, lemons,grapefruits and Mandarins — if they carry a fruit-destroying disease, called greening (HLB) disease that has no cure yet. While fruits from an HLB-infected tree is unmarketable due to its extremely sour taste and odd size, the disease has resulted in massive tree removal and significant financial losses across the US citrus industry.

“Our study shows that insecticide resistance in the pests may become an emerging problem for ACP control if effective resistance management is not practiced,” Dr Siddharth Tiwari,a postdoctoral research associate with University of Florida’s Citrus Research and Education Center (CREC), said.

The new study, published in the journal Pest Management Science, was conducted to document resistance levels in Florida populations of ACP to commonly used insecticides. Baseline susceptibility data for both adult and immature ACP were developed using a laboratory susceptible population as a comparison. Five field-collected populations of ACP were tested to estimate susceptibility levels in response to 12 insecticides.

The researchers found that certain populations of ACP have developed higher level of resistance to the insecticides,posing a great threat to the citrus industry that accounts for over USD 9 billion in Florida alone.

Dr Tiwari along with his colleagues in the Department of Entomology at CREC are working to manage psyllid, which will in turn reduce the disease spread. Their findings have called for the judicious use of insecticides to prevent the resistance from developing to high levels. ”These findings come at the right time when researchers and citrus growers are also working to fight this pest and HBL disease,” Tiwari said.

For further queries please contact:

Nikky Gupta/ Shaida Sharma
9999886136/ 8800138467

The applications of Nanotechnology are now evident in almost each and every field of Science & Technology. NSTC has several domain specific programs like:

Nanotechnology Sensitization Program (6 Months): Nanotechnology Sensitization Program is first of its kind in India. It focuses on providing entry level information for all those who are interested in this exciting & rapidly expanding field of Nanoscience & Nanotechnology. This program will lead to higher levels of knowledge base which in turn is quite useful for career development and new job opportunities.

Introductory Program in Nanotechnology (3 Months): This explains the basic perception & exploration of this emerging field. It tops this with applications of technology in various sectors to aware the implementations of Nanotechnology at various levels. It is ideal for those who want to explore science and are curious about demand of Nanotechnology in daily life.

Integrated Program in Nanotechnology (9 Months): Integrated Program in Nanotechnology explains the integration of physics, biology and chemistry at the nanometer scale and tops this with applications of technology and engineering to ensure know-how of practical implementations of Nanotechnology at various levels.

Industry Program in Nanotechnology (6 Months): The industry level program is an advanced program meant to enhance the knowledge base of participants who have a very basic knowledge of Nanotechnology. It equips the participant to be able to understand the practical and business aspects of various Nanotechnology techniques and materials from the point of view of the industry.

Nanoelectronics & Its Industrial Applications (6 Months): For the budding engineers and professionals it is very important to know and understand the latest that when they join the industry they are capable of giving back to the industry what they have learned and gained during their academic pursuits.

Bionanotechnology & Its medical Applications (6 Months): The program aims to give a participant a thorough grasp of this amazing new application of Nanotechnology. It equips the participant to explore further and discover the power of the nano-level in offering relief to humankind from so-called incurable maladies. While the subject matter is covered in great depth, a lot of attention is paid to ensure that the participant understands the practical applications of the study material in the domain of Nano-scale Biotechnology.

Nanopharmaceuticals & Its Industrial Applications (6 Months): Nanopharmaceuticals offer the ability to detect diseases at much earlier stages and the diagnostic applications could build upon conventional procedures using nanoparticles. Nanopharmaceuticals represent an emerging field where the sizes of the drug particle or a therapeutic delivery system work at the nanoscale.

Nanotechnology Teachers’ Training Program (3/6 Months): Nanotechnology Teacher’s Training Program explains the integration of physics; biology and chemistry at the nanometer scale, and tops this with applications of Nanotechnology and engineering to ensure know-how of practical implementations of Nanotechnology at various levels.

NSTC is a primary player in the upcoming field of Nanotechnology. NSTC functions as a unique body in India of Nanotechnology Certification provider, and also provides services like Technology Transfer, Consultancy & Outsourcing.

NSTC is mainly providing the training Programs in domains like
• Electronic Industry
• Pharmaceutical Industry
• Biotechnology

About NSTC (website: www.nstc.in)

Nano Science and Technology Consortium a uniquely positioned body that acts as a Nanotechnology platform. NSTC brings together various stakeholders in the Nanotechnology arena and binds them together, enabling them to reach their final destinations with ease. For example, we bring together entrepreneurs and Nanotechnology researchers, so that entrepreneurs can set up profitable businesses, and researchers can get the satisfaction of watching their research work turn into a marketable product. We bring together students and the academia, so that students can gain knowledge in nanotechnology, and the academia can impart it.

NSTC has been performing this role to perfection since the past six years, and has been expanding its domain to include researchers, government bodies, corporate houses, students, businessmen and technocrats, to help them benefit mutually from each other.

Media Contact:

Gian Prakash
Manager
(Ph) 0120-4781215, 09958161117
E-mail: gian@nstc.in
Website : www.nstc.in

Based on the findings of this Best Practices research, Frost & Sullivan is proud to present the 2011 Europe Company of the Year Award in Synthetic Biology to Evolva Holding SA. Their benchmarking criteria included growth strategy excellence, growth implementation excellence, degree of innovation with products and technologies, leadership in customer Value and market penetration potential.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-inclass positions in growth, innovation and leadership. The company’s Growth Partnership Service provides theCEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

About Evolva
Evolva is an international, innovative synthetic biology company with a world-class research platform. Evolva strives to improve people’s lives by applying its technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Our approach differs from that of the mainstream in the
pharmaceutical and chemical industries. We have discovery partnerships ongoing both in pharma and in nutrition. In addition we have a pipeline of promising compounds aimed at infectious and cardio-renal indications. For more information visit www.evolva.com.
Contact:
Girija Balan
Sr. Manager, Pressman
Tel: 022-22188880
pr@pressmanindia.com
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of
these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Bangalore, INDIA, [April 27, 2011] – Lanika Solutions, provider of world-renowned technical products that contribute to the success of engineering projects has entered a distribution agreement with Reactive Systems, Inc. the leading provider of tools and services for embedded-software testing and validation.

Lanika Solutions will sell and provide front-line technical support for all Reactive Systems products including Reactis, the Reactis for C Plugin, and Reactis for C. All products help engineers increase the quality of embedded software while decreasing verification and validation costs. The first two products support a model-based design process while the later supports a C-code process.

Reactis provides advanced verification and validation of Simulink models through automated test generation, requirements checking, and advanced debug. The Reactis for C Plugin offers white-box testing of the C code portions of models (S-Functions and Stateflow custom code). Reactis for C generates comprehensive yet compact tests from C code, finds runtime errors, and tracks coverage.

“We are very pleased to be partnering with Lanika Solutions,” noted Reactive Systems CEO Steve Sims. “Their considerable expertise with software tools for engineering, science, and math positions Lanika very well to sell and support all of our products.”
“We are delighted to enter this partnership with Reactive Systems having varied experience in providing robust, cutting-edge technology solutions especially in embedded-software testing and validation,” says Zakir Hussain, Director of Lanika Solutions. “Through our association, we shall further extend our reach in Indian markets by introducing these tools which will greatly benefit our clients.”

About Lanika Solutions

Lanika Solutions is provider of technical computing software & high-end hardware tools for engineers and scientists in industry, government and education. The Company partners with reputed principals developing industry leading solutions that help a wide base of clients throughout the Indian sub-continent solve the toughest engineering problems.
For more information, visit www.lanikasolutions.com
About Reactive Systems

Reactive Systems, founded in 1999, is a privately held, US-based company. Its products are used by companies around the world in the automotive and aerospace industries as well as in academia.

For more information, visit www.reactive-systems.com

Jaipur, 10 December. Morarka Foundation, promoters of natural agriculture in the country since last 10 years, has recently tied-up with GTZ Saudi Arabia to develop their organic farming sector.
“With our vast experience and knowledge in the farming segment, the Agriculture Ministry of Kingdom of Saudi Arabia selected Morarka Foundation as resource organisation for technology transfer to develop organic agriculture in that country,” the Foundation’s Executive Director Mukesh Gupta said.
The Foundation is already providing technological know-how to countries like Malaysia, Singapore, Thailand and Australia. “with Saudi Arabia, we have now entered into Middle East countries with our expertise. We are now looking to expand in the Middle East and other Asian nations in developing organic agriculture,” he said.
Saudi Arabia mainly produces date palm, grains and horticultural products, Gupta said, “We will take step by step approach in converting farming in Saudi Arabia. We will begin with date palm and then extend to grains, vegetables and fruits.”
Presently, 15000 hectares are under certified organic farming in Saudi Arabia and another 30000 hectares are under conversion. It takes about three years for converting any farmland into an organic farm.
A 30-member delegation, including 20 progressive farmers and 10 senior officials from the agriculture ministry of Saudi Arabia will visit Foundation’s organic project sites in Bhuj in Gujrat, Patankalan and Nawalgarh in Rajasthan to have first hand experience, he said. Besides Saudi Arabia has also participated in 3-day international organic trade fair – BioFach India 2010 that began in Mumbai on 7th December 2010 at Bombay Exhibition Centre, Goregaon.
“The overall objective of the tie-up is to develop a state-of-art organic sector in production, marketing and certification to satisfy consumer demands for healthy organic food in Saudi Arabia,” GTZ Team Leader Dr. Marco Hartmann said.
“GTZ also aims to offer opportunities to farmers and producers within the domestic and export markets to keep up with global food production quality standards.” He said.
Saudi Arabia is looking to convert its livestock into ‘organic livestock’ , however, this will take tine, he added.
* * * *

The days when the Indian pharmaceutical industry was synonymous with cheap generic drug production are passing. While generics continue to play a major part in the industry’s success, many companies have started down the long road of drug discovery, novel product development and pharma services. With high-quality research, low-cost manufacturing facilities and educated personnel, the Indian pharmaceutical industry presents both a competitive threat and partnering opportunities. ( http://www.bharatbook.com/detail.asp?id=160235&rt=The-Indian-Pharmaceutical-Industry-New-Strategies-in-a-Changing-World.html )

A significant international industry
India is the world’s fourth largest producer of pharmaceuticals by volume, accounting for around 8% of global production. In value terms, production accounts for around 1.5% of the world total. The Indian pharmaceutical industry directly employs around 500,000 people and is highly fragmented. While there are around 270 large R&D based pharmaceutical companies in India, including multinationals, government-owned and private companies, there are also around 5,600 smaller licensed generics manufacturers, although in reality only around 3,000 companies are involved in pharmaceutical production. Most small firms do not have their own production facilities, but operate using the spare capacity of other drug manufacturers.

A new approach
The advent of pharmaceutical product patent recognition in January 2005 changed the ground rules for Indian companies. In the run up to the new post-patent era and since, the Indian industry has been evolving. R&D departments are moving away from reverse-engineering in favour of developing novel drug delivery systems and discovery research. It is anticipated that the experience of selling generics in the international market will hold Indian companies in good stead for selling their own branded products to these markets in the future.

Focus on…current and future markets
The dynamics of the domestic Indian market have always encouraged Indian industry to pursue overseas lines of business. Expansion comes at a cost and some companies have had to restructure. In June 2009, Wockhardt divested its German business, esparma and more recently, in March 2010, Orchid sold its generic injectable formulations business to Hospira but came out of the deal with a long term supply agreement for its APIs.

INDIA
India remains an important market for the vast majority of Indian companies. The indigenous industry supplies around 70% of the country’s pharmaceuticals. The proportion of revenue derived from India depends largely on the strategy of the individual company and its penetration into overseas markets. For example, while Zydus Cadila aims to grow rapidly overseas, India remains its most important market, accounting for 55.8% of revenue in fiscal 2008/09. India is also Cipla’s key market, generating almost half of the company’s revenue in 2008/09, although this percentage has been declining in recent years as the company has increasingly targeted overseas markets. Other companies, such as Dr. Reddy’s, are less reliant on the Indian market; in 2008/09, India contributed just 17% of the company’s global revenue.

For more information kindly visit : The Indian Pharmaceutical Industry : New Strategies in a Changing World

Related Reports

Pharmaceuticals: Global Industry Overview

http://www.bharatbook.com/detail.asp?id=134348&rt=Pharmaceuticals-Global-Industry-Overview.html

Pharmaceuticals – Global Group of Eight (G8) Industry Guide

http://www.bharatbook.com/detail.asp?id=135896&rt=Pharmaceuticals-Global-Group-of-Eight-G8Industry-Guide.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook

San Mateo, CA – Red Herring announced its Top 100 Asia Award in recognition of the leading private companies from Asia, celebrating these startups’ innovations and technologies across their respective industries.

Red Herring’s Top 100 Asia list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.

“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Asia to the Top 100 Winners. We believe Vanuston Intelligence embodies the vision, drive and innovation that define a successful entrepreneurial venture. Vanuston Intelligence should be proud of its accomplishment, as the competition was very strong.”

Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Asia.

Hyderabad, India, 18th October 2010: Bharat Biotech  (www.bharatbiotech.com) today announced the launch of India’s first indigenously developed cell culture H1N1 swine flu vaccine under the brand name ‘HNVAC™’.

HNVAC™ is the only developing world flu vaccine to be manufactured in cell culture, a highly sterile and controlled manufacturing process, instead of eggs.

HNVAC™ was tested extensively in one of the largest Phase I, II and III clinical trials for flu vaccines in India and has proved that it is safe and well tolerated.

Making the announcement Bharat Biotech’s Chairman and Managing Director, Dr. Krishna Ella, said we are pleased to announce the launch of HNVAC™ to help prevent the spread of H1N1 pandemic influenza, which can spread rapidly with a high rate of disease and death. Bharat Biotech is proud to develop and offer this vaccine with the best USFDA recommended cell culture technology for Indian consumers. While there’s certainly widespread and growing concern around H1N1, there are number of people who did not get a flu shot last year. Our goal right now is get the flu vaccine easily accessible and at affordable cost to high risk groups he added.

“The key benefit of our cell culture vaccine is its potential to scale up and produce large quantities quickly as required, it also has a much more sterile and faster production cycle, without the external dependence on eggs and thus enabling quicker response times in the event of a pandemic. We’ll also explore ways in which Bharat Biotech can assist consumers and government agencies throughout this and subsequent flu season to get HNVAC™ flu shot,” Dr. Ella added. Bharat Biotech’s goal is to develop world class technologies and offer them to the Indian population and for emerging markets. We are proud to offer this technology to global populations.

Bharat Biotech received the approval from the Drugs Controller General of India earlier this month to launch HNVAC™ vaccine. HNVAC was developed with approved strains from WHO and CDC Atlanta. This single dose vaccine has been developed by Bharat Biotech’s scientists at the Genome Valley facility in Hyderabad. HNVAC™ places Bharat Biotech’s superior, clean, safe and controlled mammalian cell culture technology ahead of several multinational and Indian vaccine companies which still use eggs for manufacturing. USFDA has discouraged the use of egg based vaccines due to adverse reactions from egg based proteins, especially in children.

Bharat Biotech expects the demand for flu vaccines in vaccine in India to rise as consumer’s awareness about the disease increases and they are more concerned about getting the flu than they were a year ago. HNVAC™ will be made available in the private market and through government procurement agencies. HNVAC™ vaccine will be competitively priced as Bharat Biotech is committed to ensuring pricing does not become a barrier for consumers to access its vaccines.

About Bharat Biotech

Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research.

Bharat Biotech is one of the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA). Bharat Biotech is also a WHO prequalified manufacturer of Hepatitis-B vaccines for supply to UNICEF and global procurement agencies. Bharat Biotech is one of the largest manufacturer of anti-rabies vaccines in India. INDIRAB® is a market leader in India and several countries globally. Bharat Biotech also manufactures vaccines for typhoid, polio, and pentavalent combination vaccines.

Bharat Biotech is a market leader in wound healing segment with its REGEN-D, epidermal growth factor for diabetic foot ulcers, burns and wound healing. www.bharatbiotech.com

Industry and policy makers should work together to find ways to improve access to life saving vaccines DCVMN says
• Equally significant is the need to promote policies that will expand the incentives for vaccine research
• An Action Plan will also be made to expand DCVMN collaboration with GAVI alliance which works towards saving children’s lives and protect people’s health by increasing access to immunizations in poor countries.

Hyderabad, India, September 14, 2010: What is expected to emerge at 11th Annual DCVMN General Meeting to held in Hyderabad from September 13-16, 2010, will be the prescription for the vaccine industry that can help the industry overcome hurdles such as a strong distribution infrastructure, inspire more innovation, and strengthen collaboration with multi lateral agencies in addition to encouraging diet of incentives by Government for the development of vaccines that will motivate the industry. The three days 11th Annual General Meet of DCVMN is hosted by Bharat Biotech. 125 participants from 31 vaccine manufacturers representing 14 countries & 12 international agencies will be participating in this year’s annual meet.

In recent times DCVMN has played a much broader role and has a greater influence in Global Immunization and infectious disease control initiatives. It has played a critical role in developing the Immunization Vision and public health strategies for the Developing World. The goal of DCVMN meet is to provide an opportunity for its partners to participate in shaping a global research and development strategy. Its objective is to also analyze the current status of vaccine research and development and identify opportunities for vaccine research and development within WHO review of new vaccine technologies. DCVMN also reviews opportunities and bottlenecks in vaccine research, development and introduction of new products in the global markets.

In his address Dr. Akira Homma, President of DCVMN said DCVMN provides 2/3rd of the vaccines used in the world. The DCVMN is an important partner in the Global Immunization agenda as its goals are aligned to GAVI’s (Global Alliance for Vaccine Immunization). Our objective is to increase participation of our members in GAVI and strengthen their interest in global networking and collaboration. According to the WHO projections 2010 the number of future deaths averted as a result of GAVI support provided since 2000 is 5 million.

In his talk Dr. Krishna Ella, CMD of Bharat Biotech urged the business community and policy makers to work together to find ways to improve access to available vaccines. He also highlighted the need to create an environment that would stimulate innovation and further research into new vaccines, particularly for neglected diseases that are endemic in the emerging markets world such as malaria, rabies, and seasonal flu. It is equally important issues related to vaccines need to receive “bigger” attention from policy makers concerned about public health.

Thanks to the advent of molecular biology, people have a far better and deeper understanding of the biology of both the organisms they need to protect against and the human body’s means to fight back. Dr. Ella added.

Some of the hard issues facing the industry and the increasing role of DCVMN in the global market will be some of the topics expected to come up for discussion during this year’s meeting. DCVMN experts are expected to offer implemental prescriptions to tackle these challenges for major issues such as the WHO Pre Qualification hurdles, new challenges to enter into global vaccine market, issues and obstacles that preclude taking advantage of existing opportunities in the global market. Collaboration between DCVMN and multilateral organisations such as WHO, UNICEF will also be highlighted during the annual meet.

DCVMN will also emphasize the need to improve co-operation and networking among DCVMN members and find ways to ink new possibilities that will help produce new products required by global market among DCVMN Labs. The discussion will also include the major issues that preclude the incorporation of new technologies of vaccine production.

The critical success factors for improving partnership between emerging countries manufacturers to address public health needs in the vaccine industry and how the international and multilateral organisations can contribute better to address the need of expansion of DCVMN production capacity are some the issues DCVMN meet will address going forward Dr. Akira Homma said.

Formed in 2000 DCVMN’s goal is to provide quality vaccines at affordable prices to the developing world, DCVMN today boasts of 19 members of which 7 members are WHO pre-qualified. The full members of DCVMN network are Argentina, Brazil, China, Cuba, Egypt, India, Indonesia, Iran, Mexico, Romania, South Africa, South Korea, Thailand and Vietnam. Vaccinology institutions (WHO, IVI, RIVM/NVI) are resources for technical support. Members include – Anlis, Bharat Biotech, Biological E, Bio Pharma, BioNet Asia, Birmex, China National Biotech Group, Fiocruz, Finlay Institute, Indian Immunologicals, Instituto Fundaco Butantan, Ivac, LG Life Sciences, Panacea Biotech, Queen Saovabha Memorial Institute, Razi Vaccine & Serum Research Institute, Serum Institute of India, Sinovac Biotech, The Biovac Institute, Vabiotech, Xiamen Innovax Biotech, Zhejiang Tianyuan Bio-Pharmaceutical Vacsera and Zydus Cadilla.

ERP Software Solution for the Logistics Industry – Freight Management System at Your Service

Bangalore, India, 08.26.2010 – Freight Management System (SA-FMS) is a complete, unswerving, reasonably priced and scalable logistics ERP software solution that is readily available for helping out the mass, liquid and sundry parcel operators, freight services providers and truck operators in India. This advanced ERP solution for the logistics industry is a fully integrated group that is made to help out all types of transporters to scale out their operations.

This particular software solution for the parcel operators helps in simplifying the back office activities. It also enables the operators to add more locations and bring out better control over freight logistics with negligible additional resources. This software is quite cost effective and also has turned out in providing remarkable improvement in regards to customer satisfaction.

The unmatched domain expertise and experience of SA-FMS, that has been reining the cargo industry for more than a decade, has been helpful to many leading transport and cargo operators of India. SA-FMS also stands out to be the first fully automated service provider in the country. This unprecedented success has also enabled SA-FMS to provide logistics and freight ERP solutions for the logistics industry to more than 600 locations in India.

The process that is followed by Freight Management System is very technical and logical. The ERP software is quite systematic and contains detailed steps about each method to be followed for execution of best service in the logistics industry. The SA-FMS modules include Booking, Delivery, Trans-shipment, and Goods Movement Control. One of the best features of this software solution for the parcel operators is that, it helps in drastic cost reduction and helps in cutting down paperwork on statutory reporting.

SA-FMS has been successful in providing freight and logistics software solutions in Mumbai, Bangalore and Hyderabad and many more places across the country. They have been proved to be successful as they are quite advanced in this field and are quite scalable. All their products undergo rigorous manual and automated testing process for enabling error free performance, data accuracy and usability. SA-FMS is built on three tier architecture along with remoting technology. This in turn has resulted in well guarded database server preventing unauthorized access.

About FreightManagementSystem.com
Frieghtmanagementsysstem.com is the official website for the ERP software solution for logistics industry that can be valued by sundry, bulk and liquid truck and parcel and also freight service providers in India. Through this website, operators in the logistics industry can get full details about the working of SA-FMS and also about its numerous plus points.

For more information visit: http://www.freightmanagementsystem.com

Software Associates, Plot No. 31
Sector -19c
Vashi, Navi Mumbai-400705.
Tell: 09847005656

Medical Transcription Blog announces that Medical Coding will be in Demand for Careers in Medical

August 17, 2010 – The Medical Transcription Blog, a resource for medical coders and transcriptionists, announces that the job growth in the field is expected to remain strong through the next decade. In general, medical transcriptionists convert dictations made by physicians and other healthcare professionals by listening to and transcribing them into medical reports, correspondence, or other administrative documents. Pay for this role can range from $30,000 to $50,000 per year, with certified transcriptionists receiving approximately $7,500 per year more than their non-certified counterparts.

The qualification of certified medical transcriptionist (CMT) is given by the Association for Healthcare Documentation Integrity (AHDI). An eligibility requirement for certification is two years’ of experience as a medical transcriptionist in an acute care setting as well as passing AHDI’s CMT exam. The recommended budgeted time for the exam by AHDI is four hours. The exam is administered nationally in testing centers year round. There is an exam application fee of $10, and an exam fee of $195 for AHDI members and $275 for non-members.

According to the U.S. Department of Labor (DOL), there were roughly 105,200 medical transcriptionists in the U.S. in 2008, a figure that is projected to grow 11% per year through 2018. Employers often prefer candidates who are certified as CMTs. According to the DOL, roughly 36% of medical transcriptionists work in hospitals, and another 23% work in physicians’ offices. Others work for diagnostic laboratories, outpatient care centers, and other healthcare service offices and locations. Transcriptionists can also work remotely from a home office as well and can enjoy flexibility in their hours of work.

The Medical Transcription Blog offers a variety of resources to both medical transcriptionists as well as those interested in a career in the field, as well as resources for study and certification. The site also offers a free e-book once you subscribe as well as a free daily newsletter with powerful tips. In addition, resources and tips for getting started setting up your own medical transcription business are available on the site.

To learn more about career opportunities in medical transcription and getting certified as a CMT, please go to: http://www.themedicaltranscriptionistblog.com/review-medical-coding-pro-store

Lot 308 Catherine Mt,
Montego bay,
St. James,
Jamaica,
Tell: 876-467-3707
Email: jason@themedicaltranscriptionistblog.com

GVK Biosciences Private Limited Received AAALAC Accreditation for its Animal Facility

Hyderabad, Andhra Pradesh, India, July 12, 2010 / IndiaPRLine / — GVK Biosciences Private Limited (GVK BIO), Asia’s leading Contract Research Organization today announced that it received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International for its animal facilities.

The accreditation demonstrates GVK BIO’s commitment to high standards of animal care. AAALAC commended the organization for promoting a productive research environment that ensured high standards of humane care and use of research animals.

“It is indeed a proud moment for us. The AAALAC certification reiterates the fact that the team at GVK BIO is par excellence and provides high quality drug R&D services to its clients in a regulatory-compliant environment,” said Dr. J. B. Gupta, Senior Vice President, Collaborative Research & Biology.

The AAALAC certification will help in furthering GVK BIO’s growth in the areas of Pharmacology, ADME/DMPK, Exploratory toxicology and Animal Models. GVK BIO is the first organization in Hyderabad (http://www.aaalac.org/accreditedorgs/aaalaclistall.cfm) and only the 6th one in India to receive AAALAC certification. The endorsement is a validation of GVK BIO’s abilities to deliver world class solutions.

Editor Notes

About AAALAC International

AAALAC International is a private, non-profit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. AAALAC works with institutions and researchers to serve as a bridge between progress and animal well-being. More than 800 companies, universities, hospitals, government agencies and other research institutions in 32 countries have earned AAALAC accreditation.

About GVK BIO

GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. GVK BIO’s diverse portfolio of more than 100 customers includes Big Pharma, Agri & Life-sciences companies, leading biotechs and academic institutions. Spread across five locations in India and headquartered in Hyderabad, GVK BIO assists clients accelerate their research.

Media contact details

Sharada Alvakonda, Corporate Communications,
GVK Biosciences Private Limited,
+91 (40) 66929999/8,
sharada@gvkbio.com

Biomarkers in Breast Cancer 2010 a new research report has been released today. The report provides a detailed review of current and recently discovered breast cancer biomarkers

This report provides a comprehensive and up-to-date review of current and recently discovered breast cancer biomarkers. Today, biomarkers recommended to guide the diagnosis and treatment of breast cancer, are limited in number. In their most recent (2007) guidelines, the American Society of Clinical Oncology (ASCO) supported the case for just nine markers, based on studies carried out between 1999 – 2006.

However, recent years have seen the discovery and clinical study of significant numbers of new biomarkers and additional clinical data are now available on earlier markers not yet in common use. Collectively, these biomarkers are providing valuable insights, diagnostically and therapeutically, in key areas of breast cancer. These include diagnosis, metastasis and spread, therapy direction, response to therapy, prognosis, predisposition, drug discovery and clinical research. This report presents the studies and a utility-based classification of more than 200 breast cancer markers, reported in studies between Jan 2003 and May 2010. Going forward, many of these will very likely find valuable application in the clinic, in diagnostics, therapeutics, clinical research and drug discovery. This report also includes (at no additional cost) a six-monthly update, allowing readers to stay current with new findings over the coming year.

Overview

Over the last decade, research has generated a wealth of biological data that characterise the changes that occur in breast cancer. These findings have advanced the understanding of this disease, and allowed the development of more discriminating diagnostic methods and treatments. Cancer embraces multiple changes at the genetic, phenotypic, cellular and histological level and nowhere are these changes more evident than in the field of cancer biomarkers, which now embraces many thousands of studies: cells, animals and human. This report presents an up-to-date review of breast cancer biomarkers, with particular focus on the research of candidate molecules in controlled clinical studies.

Biomarkers

Biomarkers identified in this report include: proteins, peptides, metabolites, genes and mutations, epigenetic species and other molecules. In particular, the report identifies molecules that offer minimally invasive techniques. As part of this report, biomarkers are classified by their potential utility. These areas include: diagnosis and staging (e.g. early detection); metastasis (e.g. to lymph nodes, bone); therapy directing (e.g. single and multiple drugs); response to therapy (e.g. favourable, resistance); prognosis (e.g. of relapse ); potential drug targets and diagnostic opportunities (e.g. novel proteins up-regulated in breast cancer tissues or elevated in the circulation); biomarker source (e.g. blood, tissue , urine); type (e.g. protein, gene); and function (e.g. of gene or protein).

Easy-to-Use

This report presents findings on more than 200 proposed breast cancer biomarkers in a review that includes studies over the last eight years, through to May 2010. The report is presented in pdf format and provides the reader with an easy-to-read layout. Biomarkers are discussed and presented by their potential utility in key breast cancer areas, including diagnosis, metastasis, response to therapy, prognosis and disease predisposition. Figures and tables from this report are also provided in pdf slide format.

Opportunities

The study of biomarkers is one of the most promising and dynamic areas of cancer research today, as scientists seek to extend their understanding of the disease at the biological level. These advances are giving rise to more discriminating diagnostic tools and therapies, as well as a providing a deeper understanding of genetic and phenotypic differences at the patient level, as medicine moves ever closer to more personalised therapies. While these developments create important opportunities, this rapidly evolving field is also seeing uncertainty as interest shifts from past findings, to more promising recent advances. This report provides a comprehensive review on current opportunities in this field. In addition, through a six-monthly is provided (at no additional cost) with this report, helping readers to remain current with new advances and opportunities. informed of future opportunities.

Six-Monthly Update

The increasing availability of advanced genomic and proteomic tools is accelerating research in the cancer biomarker field, leading to the rapid growth of new findings. To keep pace with these developments, this report includes a six-monthly update, identifying the most promising advances and opportunities. This update will automatically be sent to purchasers of this report, at no additional cost.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3354/Biomarkers-in-Breast-Cancer-2010.html

or email us your query at : info@visionshopsters.com

———————————————-

Pune, 7th May, 2010; Acton Biotech launches genetic test to identify the right dose of warfarin to be given to a patient. Large research studies have shown that the unexpected response to warfarin depends on a patient’s variants of the genes. Patients who have mutations in the drug target gene (VKORC1) and drug metabolizing gene (CYP2C9) will need either a much higher dose or a much lower dose as compared to patients who do not have these mutations. This test was approved by USFDA in 2007 and was not available in India so far. Through detection of these genetic markers, doctors are better able to accurately and efficiently determine the appropriate warfarin dosage level and avoid over dosing and under dosing complications.
Background Information
Clotting of blood on external injuries is essential. But blood clot flowing inside a person’s body can have serious consequences as these clots can block an artery can cause a heart attack or block blood flow to brain and cause stroke. Internal blood clots are common in patients who have had a heart attack, heart valve replacement and major surgery. Warfarin is the second most common drug responsible for ICU admission after Insulin.
Standard recommended dose of warfarin is 5 mg per day. Some patients cannot tolerate this dose and suffer from severe internal bleeding that can be life threatening. For these patients, the dose is gradually reduced to 2.5 mg or 1 mg. On the other hand some patients show no response to the drug at 5 mg per day and are at a risk of equally dangerous blood clots. In India, 2 million people take warfarin every year to prevent blood clots, heart attacks and stroke. Warfarin is a difficult drug to use because the optimal dose varies and depends on many risk factors including a patient’s diet, infections and the use of other medications. Close to 15 % population is on both sides of the normal range.
The response to Warfarin is measured in terms of a person’s prothrombin time (PT). PT is a blood test that measures how long it takes blood to clot. The normal range is 0.8–1.2. Patients (especially children) with heart valve replacements need to take warfarin to elevate their PT to 2.5 to 3 so that the value is accepted by the body and clots don’t form around it. These patients need to be on warfarin for the rest of their life.
More about Warfarin Warfarin is an anticoagulant (blood thinner). It reduces the formation of blood clots by blocking the formation of certain clotting factors. Warfarin is used to prevent heart attacks, strokes, and blood clots in veins, arteries and lungs. It treats or prevents clots that may occur because of a type of abnormal heartbeat (atrial fibrillation) or heart valve replacement. Warfarin is also used to reduce the risk of death or blood clotting events (eg, stroke) after a heart attack. In the US, an economic study (Brookings Institute, November 2006) concluded that widespread use of warfarin sensitivity testing in the U.S. could avoid 85,000 serious-bleeding events and 17,000 strokes a year, saving healthcare costs of approximately $1.1 billion annually and improving patient care. There is not data available on the losses caused by warfarin. The USFDA as also asked pharma companies to update the labeling for the widely used blood-thinning drug, Coumadin, to explain that people’s genetic makeup may influence how they respond to the drug http://www.fda.gov/bbs/topics/news/2007/new01684.html
More about Acton Biotech Acton Biotech is the first and only laboratory dedicated to offering pharmacogenomic tests in India. As we all know, different people respond differently to the same drug. It is well known that this difference in drug response is because of genetic differences. The study of these genetic differences to predict drug response is called Pharmacogenomics. Currently we are offering tests to identify patients who are at great risk of developing severe toxicity from commonly used drugs. We collect samples from all over India and analyze them in our laboratory. Our mission is to make drugs safer and effective.
Media Contact
Sandeep Saxena
Founder and CEO Acton Biotech (India) Pvt. Ltd. 4th Floor, Banoo Coyaji Building, KEM Hospital, Rastapeth, Pune 411011 Tel : 020 32319395 Mo : 9890042670 Web : www.actonbiotech.com

“A new company named SuAyu LifeCare (P) Ltd. has been launched in Health care and wellness industry with the AIM to spread the maximum awareness about Ayurvedic science & it’s Herbal Extract Formulations”

Surat, Gujarat, India, April 20, 2010 – Mr Prakash Rakholia (MD) today announced the launch of SuAyu LifeCare (P) Ltd. SuAyu LifeCare (P) Ltd; an enterprise embarked to help people for the better health through the power of Ayurveda. The products are specially formulated from the extracts of natural herbs, highly effective which improves quality of life. The company has been providing healthcare solutions with destined to help the ailing people.

“Since many years, due to the influence of modern way of curing people’s health, our own Herbal Medicinal Scripture was in dark. Our Endeavour is to enlighten the values and faith of India’s centuries old herbal scripture and to deliver it to every needful mankind, in short we want to make people SMARTER” – Prakash Rakholia (MD).

At SuAyu, It is our constant endeavor to ensure the highest quality at each & every stage i.e. right from procuring raw materials to finished products. Our expertise, high stress on quality control & special project teams working on Total Quality Management (TQM) projects, makes quality a way of life in SuAyu.

SuAyu follows all stringent quality norms which conform to the standards of the pharmaceutical industry. These kinds of practices have been generally followed by very few Ayurvedic companies, we are one of them.

At present company has been marketing eighteen herbal formulations which are being manufactured at its state-of-the art production facility in Surat, Gujarat, India. Company has been promoting its products through unique marketing model called “Direct Selling @ Single Level”

Every products of SuAyu has big list of satisfied customers, read below what customer says about one of our very successful product FITSULIN-DM™ (for diabetes)

“I am having Diabetes for last 10 years. Glucose level has been noticed between 200-250, even after allopathic medicines. Then I heard about SuAyu LifeCare’s “FITSULIN – DM”. Just in a week, my glucose level decreased to 150-170. Even I don’t feel weakness now.” - Mr. Yogesh N. Panchal

Editor Notes

About SuAyu LifeCare (P) Ltd

SuAyu brings a new concept of Ayurveda backed by modern scientific research, latest technology and innovative solution with focusing on safe and evidence- based phytoMedicines which “Improves Quality of Life“. The price of Herbal Formulations is around Rs 380 for 60 Capsules. The interested customers have been buying Products directly through our website www.suayu.com

For additional information, contact:

Jignesh Patel

(Public Relation Officer)

E-Mail: Jignesh.patel@suayu.com

Mob. No. : 9099078400

Company’s Contact details

Address: 201, Gandhi Smruti Appartment, Parsi Street, Saiyedpura, Surat-395003.

Phone no:  +91 0261 2451451-58

Fax no: +91 0261 2427947

Website:   www.suayu.com

Sun Pharma Announces USFDA Approval for Generic Prometh® Syrup

Mumbai, Maharashtra, India, March 18, 2010 / IndiaPRLine / — Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that the USFDA has granted its subsidiary an approval for its ANDA for Promethazine Hydrochloride and Codeine Phosphate Oral Syrup, 6.25 mg/5 ml and 10mg/5ml.

This Promethazine Hydrochloride with Codeine Phosphate Oral Syrup is bioequivalent to Prometh® w/ Codeine of Actavis Mid Atlantic LLC. This product has annual sales of approximately USD 16 million in the US.

This medication is used to treat symptoms caused by the common cold, flu, allergies, or other breathing illnesses (e.g., sinusitis, bronchitis).

Prometh® is the registered trademark of Actavis Mid Atlantic LLC.

Editor Notes

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

You have received this email as your address is part of our Investor Relations and Media Contacts list. All our Press Releases and Financial updates are sent to those on the list.

• If you wish to be removed from this list or your address has been accidentally included here, then please let us know by a return email and we will remove it. All the others will continue to be on the mailing list.
• If you wish to receive emails on some other email id, please send it to us.
• If you think that somebody else from your organisation should be added to this list, then please ask him / her to send us an email and we will add.
• If you are changing jobs, please send us your new email id. We would like to be in touch with you and keep you updated on happenings at Sun Pharma.

We would be happy to host one-on-one, group and telephone meetings for updates on the Company. If you wish to setup such a meeting, feel free to get in touch with us. In-person meetings can be at our office or elsewhere depending on mutual convenience.

GVK Biosciences Opens New Clinical Pharmacology Unit in Ahmedabad
New Facility Commissioned to Meet Increasing Business Demand

Hyderabad, India, March 17, 2010/ IndiaPRLine / — GVK Biosciences (GVK BIO), Asia’s leading contract research organization announced that it has commissioned its new clinical pharmacology unit (CPU) in Ahmedabad, India. The Ahmedabad CPU adds 110 beds to GVK BIO’s existing capacity of 144 beds. The new CPU will conduct a variety of studies in healthy volunteers.

Ahmedabad was the most preferred and logical destination for expansion considering the volunteer pool accessibility and proximity to about 10 CROs and leading Pharma companies. With 3 clinical wards and 110 beds, the Unit is state-of-the-art and designed to suit all regulatory requirements. It also has special housing facilities for female volunteers. Key features of this Unit include access to special population like young women, post-menopausal women, diseased population and access to about 12,000 healthy volunteers.

GVK BIO’s Clinical Pharmacology Unit (CPU) is a top service provider of bioequivalence studies to generic pharma companies globally. The CPU unit, operational from 2004 in Hyderabad, has undergone several international audits, inspections and has key accreditations to its credit including the USFDA, DCG(I), ANVISA (Brazil), AFSSAPS (France), WHO and the Ministry of Health, Turkey. In addition to the healthy volunteer population, the Ahmedabad facility gives access to diseased population in Psychiatry, Metabolism, Cardiovascular, Neurology etc.

“The opening of the new GVK BIO Clinical Pharmacology unit reflects our commitment to offer faster recruitment solutions to our customers. The facility has been audited by the DCGI and we have initiated our first study at the Ahmedabad facility”, said Manni Kantipudi, President, GVK Biosciences.

Editor Notes

About GVK BIO

GVK Biosciences (GVK BIO) is Asia’s leading research services organization. GVK BIO provides a broad spectrum of services, stand‐alone and integrated, across the R&D value chain. GVK BIO’s diverse portfolio of more than 100 customers includes Big Pharma, Agri & Life‐sciences companies, leading biotechs, generic pharma and academic institutions. Spread across five locations in India, GVK BIO is headquartered in Hyderabad, India and employs 1600+ people assisting clients to accelerate their research and success. Please write to bdcpu@gvkbio.com for slotting a Study.

Veeda Clinical Research announced the appointment of Mr. Venu Madhav as the new Chief Operating Officer of its unit in India.

Ahmedabad, Gujarat, February 25, 2010 / IndiaPRLine / — Veeda Clinical Research announced the appointment of Mr. Venu Madhav as the new Chief Operating Officer of its unit in India.

“We are happy to have Venu join the Veeda family and we are sure that with his experience and knowledge he will help to continue Veeda grow in early clinical development and augment our position in the market as leaders in this field”, said Binoy Gardi, Group Managing Director, Veeda.

Mr. Venu Madhav is post graduate in pharmacy and having 19 years of experience in diverse areas of clinical research. He has been associated with reputed companies likes Ranbaxy and Sun Pharma especially in the growth period of these organizations. His contribution for the growth of these organizations is noticeable.

Mr. Venu carries rich experience in planning bioequivalence studies from pilot to pivotal stage for generic formulations. He has designed clinical, bioanalytical, pharmacokinetic and statistical aspects of bioavailability and bioequivalence studies. He is credited to have coordinated for more than 450 pilot and pivotal biostudies for conventional formulations and extended release formulations.

He has held the responsibility for developing complex bioanalytical methods for hormonal and peptide products apart for the effective utilization of 250 methods. He has also handled more than 150 pilot and 300 pivotal bioanalytical projects with GLP compliance. Pivotal biostudies were audited by most of the regulatory inspections and subsequent approval.

During his tenure Mr. Venu has also handled pharmacokinetic and statistical evaluation of data for ANDA/ NDA submissions. He has conducted a workshop as well on ‘Bioequivalence Studies’ for Bahrain and Oman regulatory officials.

His last stint has been with Sun Pharma Advanced Research Center (SPARC) Baroda as Sr. General Manager – Pharmacokinetic Department.

Editor Notes

Veeda Clinical Research® is a leading CRO which brings together over 20 years of clinical research expertise to deliver a unique service offering which combines the quality and experience of the West with the intellectual ability and tireless work ethic of the East.